Syndax Pharmaceuticals, Inc. (1T3.F)
Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
As of 08:18AM CEST. Market open.
| Previous close | 17.30 |
| Open | 17.40 |
| Bid | 17.40 x 80000 |
| Ask | 18.20 x 80000 |
| Day's range | 17.40 - 17.40 |
| 52-week range | 10.40 - 22.00 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 1.525B |
| Beta (5Y monthly) | 1.00 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Insider Monkey
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q1 2024 Earnings Call Transcript
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q1 2024 Earnings Call Transcript May 8, 2024 Syndax Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, everyone, and welcome to the Syndax First Quarter 2024 Earnings Conference Call. Today’s call is […]
- GuruFocus.com
Syndax Pharmaceuticals Inc (SNDX) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
Insights into SNDX's robust pipeline progress, financial health, and strategic plans for upcoming drug launches.
- Zacks
Syndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDA
Syndax Pharmaceuticals (SNDX) groundbreaking menin inhibitor, revumenib, receives FDA priority review for treating relapsed, refractory acute leukemia.
© 2024 Yahoo. All rights reserved.